Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- EUROPACE28(10) · #euag247 · 2026
- 피인용
- Web of Science 0Scopus 0
- JCR IF
- JCR 2024 7.5
- ISSN
- 1099-5129
저자
- Lee, Seunghan제1저자Univ Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
- Cho, Min SooUniv Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
- Kang, Do-YoonUniv Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
- Ahn, Jung-MinUniv Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
- Lee, Jung-BokUniv Ulsan, Asan Med Ctr, Coll Med, Div Biostat, Seoul, South Korea
- Park, Han-SuUniv Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
- An, Soo YeonUniv Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
- Wee, Seong-BongUniv Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
- Seo, Kyeong-WonUniv Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
- Oh, Yong-SeogSt Marys Hosp, Cardiovasc Ctr, Seoul, South Korea
- Lee, Chang HoonVet Hlth Serv Med Ctr, Div Cardiol, Seoul, South Korea
- Choi, Eue-KeunSeoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
- Lee, Ji HyunSeoul Natl Univ, Bundang Hosp, Cardiovasc Ctr, Seongnam Si, South Korea
- Kwon, Chang HeeKonkuk Univ, Med Ctr, Div Cardiol, Seoul, South Korea
- Park, Gyung-MinUlsan Univ Hosp, Div Cardiol, Ulsan, South Korea
- Choi, Hyung OhSoon Chun Hyang Univ Hosp Bucheon, Div Cardiol, Bucheon Si, South Korea
- Park, Kyoung-HaHallym Univ, Med Ctr, Div Cardiol, Anyang Si, South Korea
- Park, Kyoung-Min
- Hwang, JongminKeimyung Univ Dongsan Hosp, Div Cardiol, Daegu, South Korea
- Yoo, Ki-DongSt Vincents Hosp, Div Cardiol, Suwon, South Korea
- Cho, Young-RakDong A Univ Hosp, Div Cardiol, Pusan, South Korea
- Kim, Ji HyunDongguk Univ Hosp, Div Cardiol, Goyang Si, South Korea
- 황기원Pusan Natl Univ Yangsan Hosp, Div Cardiol, Yangsan, South Korea
- Jin, Eun SunKyung Hee Univ Hosp Gangdong, Div Cardiol, Suwon, South Korea
- Kwon, OsungEunpyeong St Vincents Hosp, Cardiovasc Ctr, Seoul, South Korea
- Kim, Ki-HunInje Univ, Haeundae Paik Hosp, Coll Med, Dept Internal Med,Div Cardiol, Busan, South Korea
- Park, Seung-JungUniv Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
- Nam, Gi-ByoungUniv Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
- Park, Duk-Woo교신저자Univ Ulsan, Asan Med Ctr, Coll Med, Div Cardiol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
초록
Aims The appropriate antithrombotic regimen for diabetic patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) who are at high atherothrombotic risk remains uncertain. We evaluated whether the effects of different antithrombotic strategies differ according to diabetes status. Methods and results The EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) was a randomized trial comparing edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in patients with AF and stable CAD. The primary outcome was a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major or clinically relevant non-major bleeding at 12 months. Among 1040 randomized patients, 421 (40.5%) had diabetes. There were no differences in the incidence of the primary outcome between diabetic and non-diabetic patients [9.7% vs. 11.6%; hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.56-1.20; P = 0.30]. The incidence of the primary outcome at 12 months was significantly lower with edoxaban monotherapy than with dual antithrombotic therapy in both diabetic (6.3% vs. 13.7%; HR 0.44; 95% CI 0.23-0.83; P = 0.01) and non-diabetic patients (6.7% vs. 16.3%; HR 0.39; 95% CI 0.23-0.65; P < 0.001), with no significant interaction between diabetic status and randomized treatment strategy (P for interaction = 0.78). Conclusion The risk of primary outcome was similar between diabetic and non-diabetic patients with AF and CAD. Irrespective of diabetes status, edoxaban monotherapy led to a lower risk of a primary outcome at 12 months than dual antithrombotic therapy.
키워드
Diabetes mellitusCoronary artery diseaseAtrial fibrillationAntithrombotic strategyMELLITUSOUTCOMES
식별자
- Scopus EID
- 2-s2.0-105052872784
- WoS UID
- 001897478800001



로그인
연구물 목록으로